Vor Biopharma pivots to telitacicept with $175M funding, eyeing multi-billion potential. Risks include dilution, regulatory ...

Officials in Ruidoso, New Mexico will hold a press conference following the three deaths reported due to floods on Tuesday.

Vor Biopharma Inc. (NASDAQ:VOR) saw its stock surge by 85% after unveiling a major licensing agreement with RemeGen Co., Ltd.

For $45 million upfront, Vor Bio is gaining ex-China rights to RemeGen’s telitacicept, a first-in-class recombinant ...

Vor Biopharma gains rights to autoimmune drug telitacicept, raises capital and names a new CEO in a major strategic reset.

Shares of Vor Bio VOR have soared a staggering 265.5% in the past week compared with the industry’s rise of 0.8%. Last week, ...

The biotech, which earlier this year laid off nearly all of its staff, also announced a PIPE that will hand it $175 million ...

Equipped with a new CEO, Vor Bio is transitioning into an autoimmune player, leaving cell and gene therapy behind.

A potential $4 billion licensing deal with Vor Bio triggered a slide in RemeGen's stock price. Otsuka obtained a BCMAXCD3 ...